Bath & Body Works Analysts Slash Their Forecasts After Q3 Earnings
Avi Kapoor 11 hours ago
MarketsNewsAnalyst RatingsPrice TargetEarnings
Bath & Body Works beat Q3 estimates and raised FY26 sales outlook, but cut GAAP EPS guidance and gave weak Q4 forecasts; analysts lowered price targets.
Bath & Body Works, Inc. (NYSE:BBWI) on Thursday reported better-than-expected third-quarter results. The company raised its full-year sales forecast but issued cautious fourth-quarter guidance.
Adjusted diluted earnings of 26 cents per share beat the 12-cent consensus estimate, but declined compared to 35 cents a year earlier. Net sales fell 1% year over year to $1.58 billion but topped the $1.55 billion estimate.
For the fourth quarter, Bath & Body Works expects diluted earnings of $1.41 to $1.61 per share, below the $1.71 analyst estimate. Revenue is projected at $2.574 billion to $2.670 billion, compared with the $2.666 billion consensus estimate.
Bath & Body Works lowered its fiscal 2026 GAAP earnings forecast to between $3.09 and $3.29 per share. Its previous outlook called for $3.13 to $3.33 per share. Analysts expect $2.96 per share.
The company maintained its adjusted earnings forecast of $2.60 to $2.80 per share, compared with the estimate of $2.74. It raised its fiscal 2026 sales forecast to between $7.043 billion and $7.138 billion. Its previous outlook ranged from $6.999 billion to $7.109 billion. Analysts expect $7.105 billion.
Daniel Heaf, chief executive officer of Bath & Body Works, said, “Our third quarter results exceeded our sales and adjusted earnings per share guidance, and marks encouraging progress in our Consumer First Formula. One year after introducing this strategy, we are seeing our actions translate into results across product, brand, and marketplace.”
Bath & Body Works shares rose 1.8% to trade at $19.04 on Friday.
These analysts made changes to their price targets on Bath & Body Works following earnings announcement.
- Baird analyst Mark Altschwager maintained the stock with a Neutral and lowered the price target from $23 to $22.
- Morgan Stanley analyst Alex Straton maintained the stock with an Equal-Weight rating and lowered the price target from $22 to $21.
- Wells Fargo analyst Ike Boruchow maintained the stock with an Overweight rating and cut the price target from $25 to $24.
- BMO Capital analyst Kelly Crago maintained the stock with a Market Perform and slashed the price target from $24 to $20.
Considering buying BBWI stock? Here’s what analysts think:

Photo via Shutterstock
More on BBWI
Analyst ratings Benzinga
UBS Maintains Neutral on Bath & Body Works, Lowers Price Target to $19UBS analyst Jay Sole maintains Bath & Body Works (NYSE:BBWI) with a Neutral and lowers the price target from $22 to $19.
Analyst ratings Benzinga
JP Morgan Maintains Neutral on Bath & Body Works, Lowers Price Target to $23JP Morgan analyst Matthew Boss maintains Bath & Body Works (NYSE:BBWI) with a Neutral and lowers the price target from $24 to $23.
Analyst ratings Benzinga
B of A Securities Maintains Buy on Bath & Body Works, Lowers Price Target to $25B of A Securities analyst Lorraine Hutchinson maintains Bath & Body Works (NYSE:BBWI) with a Buy and lowers the price target from $30 to $25.
Analyst ratings Benzinga
BMO Capital Maintains Market Perform on Bath & Body Works, Lowers Price Target to $20BMO Capital analyst Kelly Crago maintains Bath & Body Works (NYSE:BBWI) with a Market Perform and lowers the price target from $24 to $20.
Analyst ratings Benzinga
Wells Fargo Maintains Overweight on Bath & Body Works, Lowers Price Target to $24Wells Fargo analyst Ike Boruchow maintains Bath & Body Works (NYSE:BBWI) with a Overweight and lowers the price target from $25 to $24.
Analyst ratings Benzinga
Morgan Stanley Maintains Equal-Weight on Bath & Body Works, Lowers Price Target to $21Morgan Stanley analyst Alex Straton maintains Bath & Body Works (NYSE:BBWI) with a Equal-Weight and lowers the price target from $22 to $21.
